The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...

In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

Gene therapy delivering protective vascular endothelial growth factor C into kidney filters reduced early diabetic kidney ...

Scientists at The University of Texas at Austin have developed a revolutionary gene-editing method using bacterial retrons ...

We are now in the second great wave of the genetic revolution, not defined by reading the human code of life, but by rewriting it.

RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics to cure common autoimmune diseases, today announced groundbreaking preclinical research that supports a nearly ...

Cathy Tie, who launched her first biotech in SF's IndieBio, now leads Manhattan Genomics in controversial push to edit human ...

Liver cells are indispensable for research—for drug testing, to better understand diseases such as hepatitis, fatty liver, cirrhosis, or liver cancer and for development of future cell therapies.

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...